The FDA has approved a content uniformity (CU) method using the Agilent TRS100 Raman quantitative pharmaceutical analysis system. The submitting company, Teva Pharmaceutical Industries Ltd., is an Agilent Raman spectroscopy customer and global leader in generics and biopharmaceuticals. In 2021, the U.S. Food and Drug Administration (FDA) approved the company’s CU method application, which was developed using the TRS100 system.